<DOC>
	<DOC>NCT01959061</DOC>
	<brief_summary>To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer</brief_summary>
	<brief_title>Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases</brief_title>
	<detailed_description>evaluate the efficacy and safety of Raltitrexed and oxaliplatin and lipiodol transcatheter arthrial chemoembolization for in refractory colorectal carcinoma with liver metastases.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1. Histologically confirmed colorectal adenocarcinoma 2. Disease limited to the liver Unresectable disease by surgery or other local therapies 3. Age &gt;18 years 4. ECOG performance status 02,Child pugh A or B 5. Expected survival â‰¥ 3 months 6. Adequate hematological, hepatic, and renal function 1. Pregnant or lactating women 2. Patients with severe organ dysfunction or failure 3. With severe cardiovascular disease, or mental 4. Extraliver metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced colorectal cancer of liver metastatic</keyword>
</DOC>